Abstract
Is there scientific evidence to support the replacement of the beta-agonist racemic albuterol with levalbuterol--that is, (R)-albuterol? The argument presented further refines the question as "Do we wish to continue to treat asthma with a mixture of albuterol, of which half is an agent with no known benefit--that is, (S)-albuterol--and which may exacerbate the disease?"
MeSH terms
-
Adrenergic beta-Agonists / administration & dosage
-
Adrenergic beta-Agonists / adverse effects
-
Adrenergic beta-Agonists / chemistry
-
Adrenergic beta-Agonists / economics
-
Adrenergic beta-Agonists / therapeutic use*
-
Albuterol / administration & dosage
-
Albuterol / adverse effects
-
Albuterol / chemistry
-
Albuterol / economics
-
Albuterol / therapeutic use*
-
Animals
-
Asthma / drug therapy*
-
Asthma / economics
-
Asthma / mortality
-
Asthma / physiopathology
-
Asthma / prevention & control
-
Cost of Illness
-
Disease Models, Animal
-
Disease Progression
-
Humans
-
Stereoisomerism
Substances
-
Adrenergic beta-Agonists
-
Albuterol